GCGennaro Citro

Gennaro Citro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gennaro Citro has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SNPs in DNA repair or oxidative stress genes and late subcutaneous fibrosis in patients following single shot partial breast irradiation

    by Elisabetta Falvo, Lidia Strigari, Gennaro Citro, Carolina Giordano, Genoveva Boboc, Fabiana Fabretti, Vicente Bruzzaniti, Luca Bellesi, Paola Muti, Giovanni Blandino, et al.

    The aim of this study was to evaluate the potential association between single nucleotide polymorphisms related response to radiotherapy injury, such as genes related to DNA repair or enzymes involved in anti-oxidative activities. The paper aims to identify marker genes able to predict an increased risk of late toxicity studying our group of patients who underwent a Single Shot 3D-CRT PBI (SSPBI) after BCS (breast conserving surgery).


  • Open Access

    Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors

    by Enrico P Spugnini, Alfonso Baldi, Sabrina Buglioni, Francesca Carocci, Giulia Milesi de Bazzichini, Gianluca Betti, Ilaria Pantaleo, Francesco Menicagli, Gennaro Citro, Stefano Fais

    Background: The treatment of human cancer has been seriously hampered for decades by resistance to chemotherapeutic drugs. Mechanisms underlying this resistance are far from being entirely known. A very efficient mechanism of tumor resistance to drugs is related to the modification of tumour microenvironment through changes in the extracellular and intracellular pH. The acidification of tumor microenvironment depends on proton pumps that actively pump protons outside the cells, mostly to avoid intracellular acidification. In fact, we have shown in pre-clinical settings as pre-treatment with proton-pumps inhibitors (PPI) increase tumor cell and tumor responsiveness to chemotherapeutics. In this study pet with spontaneously occurring cancer proven refractory to conventional chemotherapy have been recruited in a compassionate study.Methods: Thirty-four companion animals (27 dogs and 7 cats) were treated adding to their chemotherapy protocols the pump inhibitor lansoprazole at high dose, as suggested by pre-clinical experiments. Their responses have been compared to those of seventeen pets (10 dogs and 7 cats) whose owners did not pursue any other therapy than continuing the currently ongoing chemotherapy protocols.Results: The drug was overall well tolerated, with only four dogs experiencing side effects due to gastric hypochlorhydria consisting with vomiting and or diarrhea. In terms of overall response twenty-three pets out of 34 had partial or complete responses (67.6%) the remaining patients experienced no response or progressive disease however most owners reported improved quality of life in most of the non responders. On the other hand, only three animals in the control group (17%) experienced short lived partial responses (1-3 months duration) while all the others died of progressive disease within two months.Conclusions: high dose proton pump inhibitors have been shown to induce reversal of tumor chemoresistance as well as improvement of the quality of life in pets with down staged cancer and in the majority of the treated animals PPI were well tolerated. Further studies are warranted to assess the efficacy of this strategy in patients with advanced cancers in companion animals as well as in humans.


  • Open Access

    Tumor Suppressors and Cell-Cycle Proteins in Lung Cancer

    by Alfonso Baldi, Antonio De Luca, Vincenzo Esposito, Mara Campioni, Enrico P. Spugnini, Gennaro Citro

    The cell cycle is the cascade of events that allows a growing cell to duplicate all its components and split into two daughter cells. Cell cycle progression is mediated by the activation of a highly conserved family of protein kinases, the cyclin-dependent kinases (CDKs). CDKs are also regulated by related proteins called cdk inhibitors grouped into two families: the INK4 inhibitors (p16, p15, p19, and p18) and the Cip/Kip inhibitors (p21, p27, and p53). Several studies report the importance of cell-cycle proteins in the pathogenesis and the prognosis of lung cancer. This paper will review the most recent data from the literature about the regulation of cell cycle. Finally, based essentially on the data generated in our laboratory, the expression, the diagnostic, and prognostic significance of cell-cycle molecules in lung cancer will be examined.


  • Open Access

    Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: an approach to improve the therapeutic index of highly toxic chemotherapy drugs

    by Enrico P Spugnini, Sylvie M Renaud, Sabrina Buglioni, Francesca Carocci, Emanuele Dragonetti, Raffaele Murace, Pierluigi Cardelli, Bruno Vincenzi, Alfonso Baldi, Gennaro Citro

    Cancer is one of the most difficult current health challenges, being responsible for millions of deaths yearly. Systemic chemotherapy is the most common therapeutic approach, and the prevailing orientation calls for the administration of the maximum tolerated dose; however, considerable limitations exist including toxicities to healthy tissues and low achievable drug concentrations at tumor sites. Electrochemotherapy (ECT) is a tumor treatment that combines the systemic or local delivery of anticancer drugs with the application of permeabilizing electric pulses. In this article we evaluate the capability of ECT to allow the use of cisplatin despite its high toxicity in a spontaneous feline model of soft tissue sarcoma. A cohort of sixty-four cats with incompletely excised sarcomas were treated with cisplatin-based adjuvant ECT and monitored for side effects. Their response was compared to that of fourteen cats treated with surgery alone. The toxicities were minimal and mostly treated symptomatically. ECT resulted in increased local control (median not reached at the time of writing) with a mean time to recurrence of 666 days versus 180 of controls. We conclude that ECT is a safe and efficacious therapy for solid tumors; its use may be considered as part of strategies for the reintroduction of drugs with a narrow therapeutic index in the clinical protocols.


  • Electrochemotherapy for the Treatment of Multiple Melanomas in a Horse

    by Enrico P. Spugnini, Gian Lorenzo D' Alterio, Ivan Dotsinsky, Tzvetan Mudrov, Emanuele Dragonetti, Raffaele Murace, Gennaro Citro, Alfonso Baldi


  • Open Access

    Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery

    by Elisabetta Falvo, Lidia Strigari, Gennaro Citro, Carolina Giordano, Stefano Arcangeli, Antonella Soriani, Daniela D'Alessio, Paola Muti, Giovanni Blandino, Isabella Sperduti, et al.

    To evaluate the association between polymorphisms involved in DNA repair and oxidative stress genes and mean dose to whole breast on acute skin reactions (erythema) in breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery.


  • Open Access

    Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy

    by Enrico P Spugnini, Gennaro Citro, Stefano Fais

    The vacuolar ATPases are ATP-dependent proton pumps whose functions include the acidification of intracellular compartments and the extrusion of protons through the cell cytoplasmic membrane. These pumps play a pivotal role in the regulation of cell pH in normal cells and, to a much greater extent, in tumor cells. In fact, the glucose metabolism in hypoxic conditions by the neoplasms leads to an intercellular pH drift towards acidity. The acid microenvironment is modulated through the over-expression of H+transporters that are also involved in tumor progression, invasiveness, distant spread and chemoresistance. Several strategies to block/downmodulate the efficiency of these transporters are currently being investigated. Among them, proton pump inhibitors have shown to successfully block the H+transporters in vitro and in vivo, leading to apoptotic death. Furthermore, their action seems to synergize with conventional chemotherapy protocols, leading to chemosensitization and reversal of chemoresistance. Aim of this article is to critically revise the current knowledge of this cellular machinery and to summarize the therapeutic strategies developed to counter this mechanism.


  • Open Access

    Adjuvant electrochemotherapy in veterinary patients: a model for the planning of future therapies in humans

    by Enrico P Spugnini, Gennaro Citro, Alfonso Baldi

    The treatment of soft tissue tumors needs the coordinated adoption of surgery with radiation therapy and eventually, chemotherapy. The radiation therapy (delivered with a linear accelerator) can be preoperative, intraoperative, or postoperative. In selected patients adjuvant brachytherapy can be adopted. The goal of these associations is to achieve tumor control while maximally preserving the normal tissues from side effects. Unfortunately, the occurrence of local and distant complications is still elevated. Electrochemotherapy is a novel technique that combines the administration of anticancer agents to the application of permeabilizing pulses in order to increase the uptake of antitumor molecules. While its use in humans is still confined to the treatment of cutaneous neoplasms or the palliation of skin tumor metastases, in veterinary oncology this approach is rapidly becoming a primary treatment. This review summarizes the recent progresses in preclinical oncology and their possible transfer to humans.


    • 3 February 2009
      • Vol. 22  (6) , 751-3

    Electrochemotherapy-induced radiation recall in a cat.

    by Enrico P Spugnini, Ivan Dotsinsky, Nikolay Mudrov, Gennaro Citro, Giovanni Caruso, Pierluigi Cardelli, Alfonso Baldi

    Electrochemotherapy is gaining popularity for the treatment of malignancies of companion animals due to its efficacy and low cost. In this paper, we describe the successful treatment of a recurring fibrosarcoma in a cat by using cisplatin selectively driven within the tumor cells by trains of biphasic pulses. The cat's tumor did not recur over the following five months, however the cat did experience severe erythema at the site of previous irradiation, followed by moist desquamation and ulcer that required debridement and prolonged therapy with steroids and antihistaminic drugs. The symptoms and the response to symptomatic therapy were strongly suggestive of radiation recall. Electrochemotherapy (ECT) should be used with caution in previously irradiated areas. Further studies are warranted in this field due to its potential as a rescue for relapsing tumors.


    • 3 February 2009
      • Vol. 22  (6) , 755-7

    Prostate as sole unusual recurrence site of lymphoma in a dog.

    by Renato Assin, Alfonso Baldi, Gennaro Citro, Enrico P Spugnini

    A ten-year-old intact male Rottweiler dog was examined for sudden onset of stranguria and pollakiuria. The dog had an intestinal lymphoma treated three years before with chemotherapy. Ultrasonographic examination of the abdomen showed a large dyshomogeneous prostate with an over-distended bladder. Cytological examination of the fine-needle aspirate from the prostate yielded a diagnosis of lymphoma. The diagnosis was confirmed by histopathological examination. The dog was treated with multi-drug chemotherapy and achieved a complete remission. The dog remained in complete remission for one year from the re-institution of chemotherapy before dying of recurrence. Lymphoma rarely invades the prostate in the dog. To the best of our knowledge this is the first report of prostatic recurrence of lymphoma in a canine patient originally affected by intestinal lymphoma and treated with chemotherapy.